Le Lézard
Classified in: Health, Science and technology
Subject: FEA

INTELLISCAN 3D Named Dental Products Report's Editor's Choice


TAMPA, Fla., May 17, 2021 /PRNewswire/ -- Intelliscan 3D is revolutionizing the industry with a simplified intraoral scanning experience. Already recognized as one of the best all-around, most cost-effective intraoral scanner to hit the market, buzz continues to build about Intelliscan 3D as Dental Products Report named Intelliscan 3D as its Editor's Choice for Intraoral Scanners.

With savings on impression materials, reduced chair-time for patients, and their speed to achieve impressions, the only remaining hurdle for practices is price. At our new price point of $9,999, every practice should be able to access the superior results the Intelliscan 3D can achieve. We are honored to have been chosen as a Dental Products Report Editor's Choice awardee, and hope that this will help us reach our goal of expanding digital dentistry through the industry."

Dental Products Report praises the open-source format of Intelliscan 3D in their editorial feature. Using the Intelliscan 3D Cloud, Clinician workflows are streamlined, enabling them to quickly outsource high-quality digital impressions to the lab of their choice. Additionally, the software is suitable for a full range of indications, including dental implants, crown and bridge restorations, clear aligners, and much more.

INTELLISCAN 3D is a powder-free, digital alternative to traditional impressions. The results feature stunning realistic color and clear margin lines for enhanced accuracy. The device is more compact in size and operates at remarkably higher speeds than competing products.

INTELLISCAN 3D's superior scanning experience uses anti-fog technology and advanced motion sensing functionality. These features allow for a user-friendly, hands-free operation with capabilities to save scans directly from the wand. With this data saving function, risks of cross contamination are significantly reduced.

Dental Products Report praises the open source format of Intelliscan 3D in their editorial feature. Using the Intelliscan 3D Cloud, Clinician workflows are streamlined, enabling them to instantly send high-quality digital impressions to the lab of their choice, their inhouse 3D printer, or in-house dental milling machine. Additionally, the software is suitable for a full range of indications, including dental implants, crown and bridge restorations, clear aligners, and much more. 

Starting at $9,999, every Dentist can enjoy Intelliscan 3D, which is a guaranteed solution to improving practice efficiency and patient satisfaction. Dental practices will unleash their fullest potential by reducing costs, saving chair time, and adding new revenue streams.

For more information, contact us at [email protected] or visit www.intelliscan3d.com.

Media Contact:
Marshall Taylor
813-435-3736
[email protected] 

SOURCE Intelliscan 3D


These press releases may also interest you

at 00:01
America's child care supply remains flat, while child care prices continue to increase, according to a new report released today by Child Care Aware® of America (CCAoA) that highlights the burden families face accessing quality and affordable child...

at 00:01
The cost of living is Gen Zs' and millennials' top societal concern, but green shoots of optimism for the economy and their personal finances are emergingNearly nine in 10 Gen Zs and millennials say purpose is important to their job satisfaction and...

at 00:00
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. ...

14 mai 2024
BioArctic AB's (publ) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for their fiscal year (FY) 2024 (April 2024 through March 2025). This would generate approximately SEK 360 M in net...

14 mai 2024
The global flow cytometry market  size is estimated to grow by USD 6038.44 million from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of about 13.12%  during the forecast period....

14 mai 2024
BioArctic AB's (publ) partner Eisai announced today that they have initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous...



News published on and distributed by: